Patient-centric digital platform on Boehringer Ingelheim clinical trials launched

Boehringer Ingelheim and Carebox Healthcare Solutions have launched a digital platform to provide patients, caregivers and doctors with information on the German drugmaker’s clinical trials.

Users can select from a range of condition-specific questionnaires to anonymously answer questions about a patient’s diagnosis, disease stage, and treatment history and the platform instantly matches the user to potentially relevant clinical studies, suggests nearby study site locations, and provides next step guidance.

The functions are facilitated by artificial intelligence, enabling Carebox to continuously curate and structure eligibility criteria for Boehringer trials.

“We plan to establish a next-generation platform empowering patients who consider to participate in or to learn about Boehringer Ingelheim studies and research,” said Mohammed Ali, Global Head of Digital Development, Global Clinical Operations at Boehringer Ingelheim. “In addition, we aim to support doctors to find the information they need to consult on and pursue a well-informed treatment.”

Boehringer said a lack of patient and doctor awareness of clinical study opportunities often leads to potential issues for up to75 percent of investigators who fail to enrol the target number of participants.

The company said this can lead to as much as 90 percent of all clinical trials worldwide failing to enrol patients within the target amount of time and consequently having to extend their enrolment period.